# US 2016/0250154 A1 · Film delivery system for active ingredients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250154 A1
- Document ID: US20160250154A1
- Status: Published application
- Kind: A1
- Application number: 14/926,227
- Filed: 2015-10-29
- Published: 2016-09-01
- Earliest claimed: 2013-03-15
- Assignees: Monosol Rx, LLC
- Applicants: MonoSol Rx, LLC
- Inventors: Garry L. Myers
- Web page: https://patentgrep.com/patent/US20160250154A1

## CPC

- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1682: {Processes}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 31/569: substituted in position 17 alpha, e.g. ethisterone
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.

## Claims

### Claim 1

A method of forming a stabilized solid form of an active agent in a solid matrix wherein said solid form is present in the form of nanoparticles, microparticles, or combinations thereof, with said method, comprising the steps of:
a. combining an active agent and an excipient to form an active complex having a melting point less than or equal to about 100° C.;
b. providing a mixture of said a active complex a having a melting point less than or equal to about 100° C., said active complex comprising an active agent and an excipient, and at least one water soluble polymer;
c. adding at least a portion of said mixture to a solvent, said solvent being heated to a temperature above said melting point of said active complex whereby said active complex melts and forms a liquid dispersion of the active complex in the solvent; and
d. rapidly evaporating the solvent to form a solid matrix containing a stabilized solid dispersion of said active complex in said solid matrix, wherein said active complex is present in the form of nanoparticles, microparticles, or combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said active complex is not freely water soluble.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein said excipient is selected from the group consisting of lipids, excipients with lipid surfactive properties, liquid oily excipients, liquid solvents, and combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said stabilized, solid form of said active complex is in a form of a collection or agglomeration of nanoparticles.

### Claim 6 (depends on 1)

The method of claim 1, wherein said stabilized, solid form of said pharmaceutically active agent is in a form of a collection of microparticles.

### Claim 7 (depends on 1)

The method of claim 1, wherein said active agent is a testosterone ester.

### Claim 8 (depends on 1)

The method of claim 1, wherein said active agent is testosterone enthanate or testosterone undecanoate.

### Claim 9 (depends on 8)

The method of claim 8, wherein said excipient is selected from the group consisting of ethoxy (35) castor oil, diethylene glycol monoethyl ether, propylene glycol monocaprylate, stearoyl polyoxyl-32 glycerides, and combinations thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein said polymer is selected from the group consisting of a surfactant polymer, a cellulose polymer, and combinations thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein said solvent is heated to a temperature at least higher than the melting point of the pharmaceutically active complex.

### Claim 12 (depends on 1)

The method of claim 1, wherein said active complex comprises about 0.001 to 60% by weight of the mixture.

### Claim 13 (depends on 1)

The method of claim 1, further comprising the step of preparing a film with said stabilized solid form of said active complex.

### Claim 14 (depends on 1)

The method of claim 1, wherein the solid matrix is a film.

### Claim 15 (depends on 14)

The method of claim 14, wherein said active agent is a testosterone ester.

### Claim 16 (depends on 15)

The method of claim 15 wherein said active agent is testosterone enthanate or testosterone undecanoate.

### Claim 17 (depends on 16)

The method of claim 16, wherein said excipient is selected from the group consisting of ethoxy (35) castor oil, diethylene glycol monoethyl ether, propylene glycol monocaprylate, stearoyl polyoxyl-32 glycerides, and combinations thereof.

### Claim 18 (depends on 14)

The method of claim 14, wherein the film is a dosage unit, the active agent is present in an amount of about 10 mg or greater, and the weight ratio of excipient to active agent is about 4 to 1 or less.

### Claim 19

A method of forming a stabilized solid form of a pharmaceutically active agent in a solid matrix wherein said solid form is present in the form of nanoparticles, microparticles, or combinations thereof, with said method comprising the steps of:
a. combining an active agent and an excipient to form an active complex having a melting point less than or equal to about 100° C.;
b. providing a mixture of said active complex, and at least one water soluble polymer;
c. adding at least a portion of said mixture to a solvent, said solvent being heated to a temperature above said melting point of said active complex whereby said active complex melts and forms a liquid dispersion of the active complex in the solvent; and
d. rapidly evaporating the solvent to form a solid matrix containing a stabilized solid dispersion of said active complex in said solid matrix, wherein said active complex is present in the form of nanoparticles, microparticles, or combinations thereof; and
e. gathering the resulting residue, wherein said resulting residue comprises said pharmaceutically active agent in the form of nanoparticles, microparticles, or combinations thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein said active agent is a testosterone ester.

### Claim 21 (depends on 19)

The method of claim 19, wherein said active agent is testosterone enthanate or testosterone undecanoate.

### Claim 22 (depends on 21)

The method of claim 21, wherein said excipient is selected from the group consisting of ethoxy (35) castor oil, diethylene glycol monoethyl ether, propylene glycol monocaprylate, stearoyl polyoxyl-32 glycerides, and combinations thereof.

### Claim 23 (depends on 19)

The method of claim 19, wherein said polymer is selected from the group consisting of a surfactant polymer, a cellulose polymer and combinations thereof.

### Claim 24 (depends on 19)

The method of claim 19, wherein said solvent is heated to a temperature at least higher than the melting point of the pharmaceutically active agent.

### Claim 25 (depends on 19)

The method of claim 19, wherein said pharmaceutically active complex comprises about 0.001 to 60% by weight of the mixture.

### Claim 26 (depends on 19)

The method of claim 19, wherein said residue comprises said active complex in the form of a collection or agglomeration of nanoparticles.

### Claim 27 (depends on 19)

The method of claim 19, wherein said residue comprises said active complex in the form of microparticles.

### Claim 28 (depends on 19)

The method of claim 19, further comprising the step of preparing a film with said residue.
